Abstract
Assessing whether an acute phase response (APR) is present or not presents a complex problem to clinicians and researchers. Part of this complexity is the nature of the process itself. As a result, choosing what method to use is crucial and fraught with pitfalls. Increasingly evident is the fact that the APR is constantly present in all creatures. The problem then is, what level of the APR are we proposing to investigate? The answer to this, a decade or so ago, was easily decided by the relative insensitivity of the assays then available; we simply could not detect low levels of the markers of inflammation. In the last few years, however, C-reactive protein (CRP) assays of increasing sensitivity have shown that, in fact, the continuum of CRP values extends essentially to zero and we are able to assay down to these extremely low levels with assurance. As a result, we again have to face the decision of what constitutes a significant level of inflammation; what is the clinical cut-point? Recent information indicates that even low levels of inflammation, as assessed by sensitive assays, can provide information relevant to specific and serious disease. In other words, there would appear that there is no level of APR which does not place us at some risk for illness. Although this represents a major contribution to our level of understanding, remaining is our inability to specify where this low level process exists; cystitis, gingivitis, bronchitis, post-exercise inflammation, early malignancy, or evolving coronary artery disease.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsReferences
Johnson, A. M., Whicher, J. T., Ledue, T. B., Carlström, A., Itoh, Y., and Petersen, P. H. (2000) Effect of a new international reference preparation for proteins in human serum (certified reference material 470) on results of the College of American Pathologists Surveys for Plasma Proteins. Arch. Pathol. Lab. Med. 124, 1296–1501.
Lauder, I. (1991) United Kingdom external quality assurance schemes, annual report 10th edition. London, Department of Health.
Devleeschouwer, N., Libeer, J. C., Chapelle, J. P., Struway, C. L., Gyssels, C., L’hoir, A., et al. (1994) Factors influencing between-laboratory variability of C-reactive protein results as evidenced by the Belgian external quality assessment (EQA) scheme. Scand. J. Clin. Lab. Invest. 54, 435–440.
Thompson, D., Milford-Ward, A., and Whicher, J. T. (1992) The value of acute phase protein measurements in clinical practice. Ann. Clin. Biochem. 29, 123–131.
Wilkins, J., Gallimore, J. R., Moore, E. G., and Pepys, M. B. (1998) Rapid automated high sensitivity enzyme immunoassay of C-reactive protein. Clin. Chem. 6, 1358–1361.
Price, C. P., Trull, A. K., Berry, D., and Gorman, E. G. (1987) Development and validation of a particle-enhanced turbidimetric immunoassay for C-reactive protein. J. Imm. Meth. 99, 205–217.
Sable, K. G. and Wadsworth, C. H. (1979) C-reactive protein in early diagnosis of neonatal septicemia. Scand. J. Clin. Lab. Invest. 68, 825–831.
Wasunna, A., Whitelaw, A., Gallimore, R., Hawkins, P. N., and Pepys, M. B. (1990) C-reactive protein and bacterial infection in preterm infants. Eur. J. Pediatr. 149, 424–427.
Ridker, P. M., Hennekens, C. H., Burins, J. E., and Rifai, N. (2000) C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N. Engl. J. Med. 342, 836–843.
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., and Hennekens, C. H. (1997) Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N. Engl. J. Med. 336, 973–979.
Köenig W., Sund, M., Fröhlich, M., Fischer, H.-G., Löwell, H., Döring, A., et al. (1999) C-reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men. Results from the MONICA (Monitoring trends and determinants in cardiovascular disease) Augsburg cohort study, 1984–1992. Circulation 99, 237–242.
Kuller, L. H., Tracy, R. P., Shaten, J., and Meilahn, E. N. (1996) Relationship of C-reactive protein and coronary heart disease in the MRFIT nested case-control study: Multiple risk factor intervention trial. Am. J. Epidemiol. 144, 537–547.
Danesh J., Whincup, P., Walker, M., Lennon, L., Thompson A., Appleby, P., et al. (2000) Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Brit. Med. J. 321, 199–204.
Roberts, W. L., Sedrick, R., Moulton, L., Spencer, A., and Rifai, N. (2000) Evaluation of four automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Clin. Chem. 46, 461–468.
Roberts, W. L., Moulton, L., Law, T. C., Farrow, G., Cooper-Anderson, M., Savory, J., et al. (2000) Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin. Chem. 47, 418–425.
Köening, W. (2001) C-reactive protein and cardiovascular risk: Has the time come for screening the general population? Clin. Chem. 47, 9–10.
Ledue, T. B. and Rifai, N. (2001) High sensitivity immunoassays for C-reactive protein: Promises and pitfalls. Clin. Chem. Lab. Medicine (In Press).
Young, D. S. (1997) Effects of Preanalytical Variables on Clinical Laboratory Tests. 2nd ed. (Young, D. S., ed.), AACC, Washington, DC.
Guder, W. G., Narayanan, S., Wisser, H., and Zawta, B. (1996) Samples: From the patient to the laboratory: The Impact of Preanalytical variables on the quality of laboratory results. (Guder W. G., ed.), GTI, Verlag Darmstadt, Germany.
Ledue, T. B. and Rifai, N. (2001) Pre-analytic and analytic sources of variations in C-reactive protein measurement. In Cardiac Markers (Wu, A., ed.), Humana, Totowa, NJ, 2nd ed. (In Press)
W.H.O. Expert Committee on Biological Standardization. (1987) W.H.O. Expert Committee on Biological Standardization 37th report. W.H.O. Tech. Rep. Ser. 760. Geneva: W.H.O., pp. 21–22.
Whicher, J. T., Ritchie, R. F., Johnson, A. M., Baudner, S., Bienvenu, J., Blirup-Jensen, S., et al. (1994) New international reference preparation for proteins in human serum (RPPHS). Clin. Chem. 40, 934–938.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2003 Humana Press Inc.
About this protocol
Cite this protocol
Ritchie, R.F., Ledue, T.B. (2003). Laboratory Assessment of the Acute Phase Response. In: Winyard, P.G., Willoughby, D.A. (eds) Inflammation Protocols. Methods in Molecular Biology, vol 225. Humana Press. https://doi.org/10.1385/1-59259-374-7:343
Download citation
DOI: https://doi.org/10.1385/1-59259-374-7:343
Publisher Name: Humana Press
Print ISBN: 978-0-89603-970-4
Online ISBN: 978-1-59259-374-3
eBook Packages: Springer Protocols